475 related articles for article (PubMed ID: 19853028)
1. Development of inhalable dry powder formulation of basic fibroblast growth factor.
Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
[TBL] [Abstract][Full Text] [Related]
2. Effervescent dry powder for respiratory drug delivery.
Ely L; Roa W; Finlay WH; Löbenberg R
Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
[TBL] [Abstract][Full Text] [Related]
3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
4. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a new inhalable thymopentin formulation.
Wang L; Zhang Y; Tang X
Int J Pharm; 2009 Jun; 375(1-2):1-7. PubMed ID: 19443146
[TBL] [Abstract][Full Text] [Related]
6. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
[TBL] [Abstract][Full Text] [Related]
7. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
Cheow WS; Ng ML; Kho K; Hadinoto K
Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
[TBL] [Abstract][Full Text] [Related]
8. The influence of formulation components on the aerosolisation properties of spray-dried powders.
Rabbani NR; Seville PC
J Control Release; 2005 Dec; 110(1):130-40. PubMed ID: 16226334
[TBL] [Abstract][Full Text] [Related]
9. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
10. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
11. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents.
Jalalipour M; Gilani K; Tajerzadeh H; Najafabadi AR; Barghi M
Int J Pharm; 2008 Mar; 352(1-2):209-16. PubMed ID: 18164150
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
Pilcer G; Vanderbist F; Amighi K
Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
[TBL] [Abstract][Full Text] [Related]
13. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
Thi TH; Danède F; Descamps M; Flament MP
Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
[TBL] [Abstract][Full Text] [Related]
14. Capreomycin inhalable powders prepared with an innovative spray-drying technique.
Schoubben A; Giovagnoli S; Tiralti MC; Blasi P; Ricci M
Int J Pharm; 2014 Jul; 469(1):132-9. PubMed ID: 24747443
[TBL] [Abstract][Full Text] [Related]
15. Development of budesonide nanocluster dry powder aerosols: preformulation.
El-Gendy N; Selvam P; Soni P; Berkland C
J Pharm Sci; 2012 Sep; 101(9):3434-44. PubMed ID: 22623018
[TBL] [Abstract][Full Text] [Related]
16. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
[TBL] [Abstract][Full Text] [Related]
17. Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders.
Raula J; Thielmann F; Naderi M; Lehto VP; Kauppinen EI
Int J Pharm; 2010 Jan; 385(1-2):79-85. PubMed ID: 19879344
[TBL] [Abstract][Full Text] [Related]
18. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying.
Sansone F; Aquino RP; Del Gaudio P; Colombo P; Russo P
Eur J Pharm Biopharm; 2009 May; 72(1):206-13. PubMed ID: 18996478
[TBL] [Abstract][Full Text] [Related]
19. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
20. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims.
Thai A; Xiao J; Ammit AJ; Rohanizadeh R
Int J Pharm; 2010 Apr; 389(1-2):41-52. PubMed ID: 20080165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
